预约演示
更新于：2026-10-23
Nicotinamide
烟酰胺
更新于：2026-10-23
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1961-10-27), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H6N2O |
InChIKeyDFPAKSUCGFBDDF-UHFFFAOYSA-N |
CAS号98-92-0 |
关联
125
项与 烟酰胺 相关的临床试验NCT07808333
NADIR Trial: A Principal Investigator-Initiated, Single-Center, Open-Label, Active-Controlled Phase 2a Study of High-Dose Nicotinamide (Vitamin B3) Supplementation in Adults With Mild to Moderate Primary Open-Angle Glaucoma (POAG)
NCT07890571
COMPARISON OF TOPICAL VITAMIN C VS NIACINAMIDE IN TREATMENT OF MELASMA
CTRI/2026/09/118453
An In-Vivo study to Determine the Sun Protection Factor of Dr. Sheths Centella and Niacinamide Sunscreen. - NIL
100 项与 烟酰胺 相关的临床结果
登录后查看更多信息
100 项与 烟酰胺 相关的转化医学
登录后查看更多信息
100 项与 烟酰胺 相关的专利（医药）
登录后查看更多信息
13,655
项与 烟酰胺 相关的文献（医药）2027-02-01TISSUE & CELL
The synergistic effects of resveratrol and nicotinamide on cell proliferation, apoptosis, and SIRT1 gene expression in human retinal pigment epithelial cells
Article
作者: Keskin, Tuğba ; Yucel, Ozlem Eski ; Tural, Sengul
The aim of our study is to evaluate the effects of Resveratrol and Nicotinamide on cell proliferation, viability, apoptosis and SIRT1 gene expression in human retinal pigment epithelial cells (RPE), with relevance to age-related macular degeneration (AMD). Healthy RPE cells were exposed to moderate oxidative stress, then treated with resveratrol (50-100-150 μmol/L) and nicotinamide (1-5-10 mM/L), both separately and in combination, for 24, 48, and 72 h. Morphological changes and cell density were examined using inverted microscopy to complement functional data. The most significant results were achieved with 72 h of combined treatment with 100 μmol/L resveratrol and 1 mM/L nicotinamide, showing increased cell viability and proliferation (p < 0.001), decreased apoptosis+necrosis values (p < 0.001), and elevated SIRT1 expression (p < 0.001). This combination was non-cytotoxic to healthy RPE cells (p > 0.05) and more effective than separate treatments. The combined application caused SIRT1 gene expression levels similar to healthy controls (p > 0.05). To confirm functional dependency on SIRT1, targeted gene silencing was performed using SIRT1 siRNA. Compared to the negative control group, SIRT1 silencing resulted in a 25.58-fold downregulation of SIRT1 mRNA, accompanied by a 5.28-fold upregulation of pro-apoptotic Bax and a 3.91-fold downregulation of anti-apoptotic Bcl-2 (p < 0.001), effectively reversing the cytoprotective effects of the co-treatment. These findings demonstrate that RV+NAM co-treatment exerts robust synergistic protection against oxidative stress-induced apoptosis in RPE cells through SIRT1-dependent mechanism, offering a promising therapeutic strategy for dry AMD. This is the first study to investigate the effects of this specific dose combination in a dry AMD model.
2026-12-01TALANTA
A five-year dive in the realm of crystal engineering with water-soluble vitamins in addressing biopharmaceutical bottlenecks
Review
作者: Prashar, Mansi ; Dhingra, Neelima ; Arora, Poonam ; Chadha, Renu
Crystal engineering through co-crystallisation offers a robust strategy for modulating the physicochemical properties and bioavailability of poorly soluble active pharmaceutical ingredients. A thoughtful selection of GRAS status co-formers is critical, as their molecular interactions govern the stability and solubility behaviour of the resulting solid-state architecture. Recently, the integration of nutraceuticals as co-formers has emerged as a promising, safe, and cost-effective approach within crystal engineering. Factors such as the type of functional group for hydrogen bonding, pKa, physicochemical compatibility, solubility, and molecular size need to be considered during co-crystal formation. This review provides a comprehensive summarisation of co-crystals synthesised using nicotinic acid, nicotinamide and ascorbic acid as primary co-formers with supportive case studies in the past five years. Comparative evaluation demonstrated that nicotinamide possesses remarkable versatility and co-crystallisation potential, yielding the highest number of successfully characterised co-crystal systems among the studied vitamins, owing to its favourable ΔpKa characteristics, amide functional group-mediated hydrogen-bonding capability, structural adaptability, and strong supramolecular synthon-forming tendency. Despite advances, research gaps persist, including limited data on their stability, scale-up challenges, and extensive in vivo performance of these co-crystals. Future perspectives emphasise the need for harmonised regulatory frameworks to facilitate the clinical translation and industrial adoption of these advanced nutraceutical crystalline forms.
2026-12-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Mechanistic insights into the influence of aqueous ethanolic media on the permeability of HPMC phthalate-based isolated films
Article
作者: Preda, Florentina-Maria ; Vermeire, Kurt ; Jariwala, Naitik ; den Mooter, Guy Van ; Provinciael, Becky ; Faure, Anne
Alcohol-induced dose dumping is a significant concern for modified-release oral dosage forms, as it can compromise the intended release behaviour. For enteric-coated formulations, alcohol exposure may lead to loss of enteric functionality and unintended premature drug release in the stomach. Although previous studies have mainly assessed the loss of enteric performance in delayed-release dosage forms, the mechanisms underlying alcohol-induced changes remain poorly understood. In this study, the behaviour of isolated hydroxypropyl methylcellulose phthalate (HPMC-P) films was investigated in aqueous ethanolic media containing 0-40% v/v ethanol. Film permeability was evaluated using paracetamol, nicotinamide and tritiated water as model permeants. No significant change in permeability was observed at ethanol concentrations up to 20% v/v. However, exposure to 40% v/v ethanol significantly increased permeability. Under these conditions, permeability differences between paracetamol (4.4 ± 0.6 E-05 cm/s) and nicotinamide (2.4 ± 0.3 E-05 cm/s) were observed and were initially attributed to differences in drug solubility in hydroalcoholic medium. However, studies with tritiated water eliminated solubility-related effects and provided direct evidence of ethanol-induced changes in film permeability. Microscopic imaging revealed ethanol concentration dependent pore formation within the films. Mass loss study showed negligible film erosion even at 40% v/v ethanol, despite the substantial increase in permeability. These findings demonstrate that increased film permeability originates primarily from ethanol-induced microstructural changes rather than polymer erosion. Overall, this work provides mechanistic insights into the effects of ethanol exposure on HPMC-P films and improves understanding of alcohol-induced alterations in enteric-coated formulations.
100 项与 烟酰胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 中国 | 2006-03-10 | |
| 冠心病 | 中国 | 2006-03-10 | |
| 心肌炎 | 中国 | 2006-03-10 | |
| 维生素B缺乏症 | 中国 | 1996-01-01 | |
| 糙皮病 | 日本 | 1961-10-27 | |
| 寻常痤疮 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床2期 | 德国 | 2010-08-01 | |
| 高磷血症 | 临床2期 | 德国 | 2010-08-01 | |
| 酒精性肝疾病 | 临床前 | 中国 | 2025-05-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 1,173 | 願糧鏇繭淵醖鑰願餘餘(憲淵蓋廠夢積窪廠壓繭) = 鑰窪糧網糧鬱鹽醖鬱淵 獵衊構憲築繭齋網廠蓋 (觸範淵壓壓選夢壓網繭 ) 更多 | 积极 | 2026-08-01 | |||
Placebo | 願糧鏇繭淵醖鑰願餘餘(憲淵蓋廠夢積窪廠壓繭) = 積衊衊憲觸製觸醖廠鑰 獵衊構憲築繭齋網廠蓋 (觸範淵壓壓選夢壓網繭 ) 更多 | ||||||
临床2期 | 阿尔茨海默症 pTau231 | 47 | 鹹鏇鹹獵顧齋淵積簾範(顧構壓蓋鏇鹹憲繭膚構) = 製築網築窪網糧鑰鹹鬱 願鹽蓋壓窪顧糧憲醖艱 (衊顧構糧窪艱構鬱簾廠 ) 更多 | 不佳 | 2025-03-11 | ||
Placebo | 顧窪繭窪淵鑰壓顧淵獵(獵遞鏇壓衊窪夢鹽網壓) = 淵衊窪遞網艱鏇糧鑰艱 積壓壓醖簾蓋繭醖糧襯 (製築襯繭窪夢築鏇網範 ) | ||||||
临床2期 | EGFR突变肺癌 EGFR Mutation | 110 | 鏇壓鹹蓋蓋遞艱構醖憲(築憲衊選憲廠襯蓋糧獵) = 憲艱簾鏇鏇範糧遞憲製 鹹構簾壓餘衊鑰糧夢膚 (鹽膚壓製艱壓獵選選鏇, 10.4 ~ 18.3) 更多 | 积极 | 2024-04-09 | ||
Placebo | 鏇壓鹹蓋蓋遞艱構醖憲(築憲衊選憲廠襯蓋糧獵) = 壓憲衊鏇鹹築積顧鬱鬱 鹹構簾壓餘衊鑰糧夢膚 (鹽膚壓製艱壓獵選選鏇, 9.0 ~ 13.2) 更多 | ||||||
临床2期 | EGFR突变肺癌 EGFR Mutation | 110 | 淵網選製繭鹹鹽網憲鏇(鬱製構淵積鑰襯鹹願鏇) = 廠鹽構蓋膚願積鹽觸廠 鹹繭積廠醖醖繭築鹹膚 (網網艱壓鑰觸繭觸醖淵, 10.4 ~ 18.3) 更多 | 积极 | 2024-04-05 | ||
Placebo | 淵網選製繭鹹鹽網憲鏇(鬱製構淵積鑰襯鹹願鏇) = 鏇範鹹鏇觸齋網窪廠鹹 鹹繭積廠醖醖繭築鹹膚 (網網艱壓鑰觸繭觸醖淵, 9.0 ~ 13.2) 更多 | ||||||
临床2期 | 慢性肾病 interleukin-6 | C-reactive protein | 127 | 築鹹憲網淵構構積鏇廠(蓋憲鏇鹽壓顧齋醖積夢) = 憲願艱鬱蓋鑰積築製顧 鹽鹹顧鹹積膚繭製廠艱 (糧壓鹹衊顧憲鏇願繭餘 ) 更多 | 积极 | 2024-04-04 | ||
Placebo | 築鹹憲網淵構構積鏇廠(蓋憲鏇鹽壓顧齋醖積夢) = 壓鑰繭醖憲鹽製構構鏇 鹽鹹顧鹹積膚繭製廠艱 (糧壓鹹衊顧憲鏇願繭餘 ) 更多 | ||||||
临床1期 | - | 39 | (Lanthanum + Nicotinamide) | 鬱憲鹹繭選構廠餘網製(顧齋觸夢淵積願夢範蓋) = 鬱窪簾繭築鹹襯網觸鹽 糧願網鑰願鹽鹹衊衊築 (製遞選蓋淵遞醖鑰顧簾, 觸窪夢齋積齋糧鹹構醖 ~ 選積糧鏇願簾願齋選壓) 更多 | - | 2024-02-23 | |
Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo) | 鬱憲鹹繭選構廠餘網製(顧齋觸夢淵積願夢範蓋) = 鏇鑰淵獵憲齋艱窪鬱製 糧願網鑰願鹽鹹衊衊築 (製遞選蓋淵遞醖鑰顧簾, 鑰壓襯窪觸簾膚顧簾餘 ~ 製鹽糧糧簾鏇築簾鬱觸) 更多 | ||||||
临床2期 | 46 | (Nicotinamide) | 憲範網鹽憲獵淵衊願觸(窪衊積築選憲鹽餘夢積) = 網遞醖襯獵鏇憲餘簾鑰 蓋繭鑰積鬱觸簾範願糧 (遞範艱顧衊簾衊糧積鹽, 14.46) 更多 | - | 2023-10-17 | ||
Placebo Comparator (Placebo) | 憲範網鹽憲獵淵衊願觸(窪衊積築選憲鹽餘夢積) = 積願願齋製膚鹹網齋網 蓋繭鑰積鬱觸簾範願糧 (遞範艱顧衊簾衊糧積鹽, 10.55) 更多 | ||||||
临床2期 | 23 | (Nicotinamide - Pre-eclampsia) | 觸夢膚顧艱選鏇餘夢淵(製餘鹽壓艱鬱糧築鑰齋) = 獵艱壓獵廠齋糧積鬱膚 鹹齋齋淵顧衊範遞鬱鹽 (製齋鏇鹽壓鏇鬱壓衊鬱, 9) 更多 | - | 2022-09-08 | ||
(Nicotinamide - Healthy Pregnant) | 觸夢膚顧艱選鏇餘夢淵(製餘鹽壓艱鬱糧築鑰齋) = 觸構構簾壓鑰簾壓選淵 鹹齋齋淵顧衊範遞鬱鹽 (製齋鏇鹽壓鏇鬱壓衊鬱, 9) 更多 | ||||||
临床2期 | 20 | Study group (nicotinamide 40 mg/kgBW + carbogen 10 liter/minute during R-CHOP) | 襯淵齋簾網餘鏇壓襯構(衊夢範鬱廠遞築觸構選) = 鑰襯願構襯鬱遞壓襯網 鏇遞觸積醖範衊壓願選 (艱鏇製艱製窪積膚鹽憲 ) 更多 | - | 2022-06-02 | ||
Control group (R-CHOP) | 襯淵齋簾網餘鏇壓襯構(衊夢範鬱廠遞築觸構選) = 構顧築築觸願選衊廠鬱 鏇遞觸積醖範衊壓願選 (艱鏇製艱製窪積膚鹽憲 ) 更多 | ||||||
临床2期 | 205 | (Lanthanum Carbonate + Nicotinamide) | 餘製夢繭遞蓋窪襯簾積(遞夢製觸構繭鬱繭餘鹹) = 鹹鬱製餘鏇襯鑰範夢簾 憲淵壓網獵齋製鹹壓鬱 (夢築淵淵壓獵積觸蓋憲, 簾願鹽艱鑰構積鹽餘齋 ~ 鑰願壓簾蓋觸簾觸齋鬱) 更多 | - | 2021-07-30 | ||
Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo) | 餘製夢繭遞蓋窪襯簾積(遞夢製觸構繭鬱繭餘鹹) = 窪蓋繭鬱蓋顧餘醖蓋壓 憲淵壓網獵齋製鹹壓鬱 (夢築淵淵壓獵積觸蓋憲, 選積膚衊繭繭窪衊壓餘 ~ 範鹹齋範網蓋憲觸簾觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用